Market Signal Briefing

Video game maker Electronic Arts – known for The Sims, Maddel NFL, Plants vs. Zombies and more – could be going private soon with a valuation of roughly $50 billion.

The possible deal, first reported by The Wall Street Journal, would mark the largest ever leveraged buyout in history. A group of investors including private equity firm Silver Lake, Saudi Arabia's Public Investment Fund and Jared Kushner's Affinity Partners could unveil a deal for the publisher as soon as this week, sources told Reuters on Friday.

Shares of Electronic Arts, better known as EA, closed around 15% higher on Friday. The deal to take EA private would also mark further consolidation within the industry, after titans such as Activision Blizzard and Zynga were swooped up by even larger firms, further reducing the number of publicly listed video game companies.

EA is headquartered in Redwood City, Calif. The currently public company was founded in 1982, according to its website. 

GAMESTOP CEO TURNS NINTENDO SWITCH 2 PACKAGING DISASTER INTO ASTOUNDING CHARITY WIN

Visitors play EA Sports FC25 at the Gamescom computer gaming fair on the opening day in Cologne, Germany, on Wednesday, Aug. 21, 2024.  (Alex Kraus/Bloomberg / Getty Images)

"We create stories and deliver amazing experiences that resonate with audiences around the world and make an impact in the communities where we live, work and play," EA's website says. 

"Our values and vision as a global company continue to drive us to create a welcoming workplace, foster inclusive communities, invest in the next generation of innovators and artists, and progress our environmental initiatives," it continues. 

FOX Business reached out to EA for comment on the potential buyout, but they did not immediately respond.

MOVIE THEATERS, MOVIE STAR DISCOURAGE CHAOS DURING 'MINECRAFT' SCREENINGS

EA Sports FC 25 displayed on a TV screen and a DualSense controller are seen in this illustration photo taken in Krakow, Poland on September 30, 2024. (Jakub Porzycki/NurPhoto / Getty Images)

The company's most recent earnings results said its fiscal year had started out "strong."

"We delivered a strong start to FY26, outperforming expectations ahead of what will be the most exciting launch slate in EA’s history," Andrew Wilson, CEO of Electronic Arts, said in a statement. "From deepening player engagement in EA SPORTS to gearing up for Battlefield 6 and skate., we’re scaling our global communities and continuing to shape the future of interactive entertainment."

Electronic Arts headquarters in Redwood City, California, US, on Tuesday, July 18, 2023. (David Paul Morris/Bloomberg / Getty Images)

CLICK HERE TO READ MORE ON FOX BUSINESS

Net revenue for the company's fiscal year 2026 first quarter, which ended on June 30, showed its net revenue was $1.671 billion. 

EA's next earnings conference call is set for October 28. 

Reuters contributed to this report. 

Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF) CEO Ralph Rushton spoke with Proactive about the company’s plans to initiate a new diamond drilling program at its Challacollo silver-gold project in Chile.  

This represents the first phase of technical work on the asset since its acquisition from Mandalay Resources in 2020. 

Rushton explained that the program will include 7 to 10 diamond drill holes, totaling approximately 2,000 metres.  

This initial drilling will help assess extensions of historical mine veins and test previously unexamined structures within the project area.  

He noted, “We now have the bandwidth to take on Challacollo as well,” thanks to the recent expansion of the company's technical team. 

Challacollo is a former producing asset with a historical resource base.  

Aftermath Silver is seeking to expand this base through its own exploration efforts, although Rushton acknowledged that the current strength in the silver market has increased interest in the sector and that a potential joint venture in the future is possible.  

However, he emphasized that the company is currently focused on executing the work itself. 

With permits already in hand, drilling is expected to begin in the next one to two months, with initial results anticipated by the end of the year. 

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Investing in this stock has changed my life in more ways than one.

I own over 100 stocks. However, a small handful have made the most impactful contribution toward growing my wealth over the years.

One stock that has truly delivered life-changing returns for me is Meta Platforms (META -0.65%). Let me share why I plan to never sell another share of this technology giant.

Image source: Getty Images.

My Meta story
I initially invested in Meta Platforms (then Facebook) over a decade ago after reading a compelling buy report from a Motley Fool service that compared Facebook's digital advertising potential to Google's. At the time, shares had fallen considerably from their IPO level. The combination of price and ad-driven growth potential appeared so attractive that I bought long-term call options on the stock.

That well-timed purchase turned out to be a life-changing investment. Shares of Facebook would go on to recover from their post-IPO dip. However, instead of cashing in on my call options, I exercised them at expiration. I kept half the shares and sold the other half to help put a down payment on the first home my wife and I bought together.

Both sides of that trade have worked out well. My wife and I lived in the home for several years before selling it at a nice gain. We've gone on to buy and sell several homes, building lots of equity along the way. Now, we own what both of us consider as close to our dream home as we could have reasonably hoped to afford.

Meanwhile, Meta Platforms has become my third-largest holding. While I've occasionally bought more shares when they seemed too attractive to pass up, most of the value comes from my original purchase, which has gained over 3,000%.

Why I plan on never selling any more Meta
I don't regret selling half of my Meta shares upon exercising the call option over a decade ago. Our homeownership journey has been a very enriching endeavor, both personally and financially. However, I don't plan to sell another share, even though I rarely use Facebook or any of Meta's other social media platforms.

One reason is that Meta now pays a dividend. As someone who likes to generate passive income, Meta now provides me with a nice income stream. While Meta's stock currently has a dividend yield of 0.3%, I'm earning a hefty 10% yield on my initial cost. I expect that income stream to steadily grow as Meta increases its dividend. I can use that income stream to buy other stocks.

However, the main reason I plan to keep holding Meta is the company's optionality. When I first invested, my thesis focused on Facebook's ability to monetize its large audience through advertising. Now, Meta is far more than a social media company -- it is investing heavily in artificial intelligence, which could drive even greater value creation in the future. The company's openness to invest in emerging technologies and new market opportunities reinforces my belief that it still has a lot of growth ahead.

The company is investing heavily in AI to develop superintelligence, aiming to create AI that surpasses human intelligence. Meta's bold vision is to deliver personal superintelligence to everyone, potentially transforming the impact of technology on society.

One way Meta aims to do that is through AI devices, such as AI-powered glasses. Many people already wear glasses, including me, making them a ready-made tool for AI applications. The company is also looking to develop AI products and tools for advertising, creating, and communications.

Meanwhile, my Meta Platforms' investment thesis extends well beyond AI to other growth opportunities, including products like Quest VR headsets and cloud gaming. Meta's history of pursuing new areas with long-term potential further supports my view that it can continue growing shareholder value for years to come.

A forever stock holding for me
Meta Platforms has already been a life-changing investment for me. Looking ahead, I'm excited by its bold ambitions, including the pursuit of personal superintelligence and a steadfast commitment to leadership in innovation. The company's ability to adapt and grow is a core reason why I'm committed to holding my Meta stock for the long haul. For me, it's more than an investment -- it has become a cornerstone of my portfolio.

Matt DiLallo has positions in Alphabet and Meta Platforms. The Motley Fool has positions in and recommends Alphabet and Meta Platforms. The Motley Fool has a disclosure policy.

Nvidia's management believes global spending on data centers will accelerate over the next five years.

With a market cap of around $4.3 trillion as of this writing, Nvidia (NVDA 0.27%) is the world's largest company. However, the company's leadership believes its market cap could go much higher, and it has fairly solid data to back that premise up.

During Nvidia's fiscal 2026 Q2 earnings call, executives unveiled a jaw-dropping growth projection, and if they're right, by 2030, Nvidia could be worth $15 trillion or more. That would amount to approximately 250% upside from today's share price.

Image source: Getty Images.

GPUs are in huge demand
Nvidia makes graphics processing units (GPUs), which are specialized parallel processing chips that were originally designed to speed up the rendering of video game graphics. Back in the late 1990s, video game software featured some of the most demanding workloads a computer was likely to face. But the specific tasks that were the most problematic for a standard central processing unit (CPU) could be handled rapidly by a parallel processor. So various companies, including Nvidia, developed GPUs -- the right tool for the problem.

Eventually, it became clear that GPUs were useful in a host of other situations in which computational problems could easily be broken down into many small pieces that could be solved simultaneously -- engineering simulations and mining cryptocurrency, among others. However, one use case for GPUs surfaced that has dwarfed all the others: training and powering artificial intelligence (AI) models. And this market for the chips only looks to be getting bigger.

Over the past 12 months, Nvidia's revenue totaled $165 billion, and it's still growing at a rapid pace. Wall Street analysts project that in the current fiscal year (ending Jan. 2026), Nvidia's top line will hit $206 billion, but even that amount is nothing compared to where management believes the business could go by fiscal 2030.

Data by YCharts.

During the late-August earnings call, management discussed the AI data center market's growth trajectory. Currently, they estimate companies will spend $600 billion this year on AI-related capital expenditures (capex) with the bulk of that coming from just four hyperscalers -- Amazon, Microsoft, Alphabet, and Meta.

Considering data center revenue made up 89% of Nvidia's top line in the past year, the company could end up claiming as much as 30% of that capex spending. And there's more: By 2030, Nvidia estimates global data center capex could total $3 trillion to $4 trillion.

While some investors may be quick to write off this massive market projection, data centers take years to build. The process includes identifying a location, sourcing power, designing the facility, building it, and outfitting it with computing equipment. This means many of the data centers companies are announcing plans for in 2025 won't be operating until 2026 and beyond. So AI hyperscalers (and other big enterprise buyers) must coordinate chip supply with Nvidia. Otherwise, they could face GPU shortages for their data center buildouts.

So while Nvidia's forecast deserves scrutiny, investors should also consider what it means for the stock if that forecast proves accurate.

Nvidia could be a $15 trillion company by 2030
If Nvidia's market forecast pan out, its path to becoming a $15 trillion company by 2030 is fairly clear. Based on the midpoint of its market projection, $3.5 trillion, the company's revenue can top $1 trillion by 2030 assuming it continues to capture a 30% share of that spending.

Combined with Nvidia's strong net income margin, currently 52%, its profits could climb to $500 billion by the end of the decade. Put it all together, and the stock would only need a forward earnings multiple of approximately 30 (it currently trades at 40 times forward estimates) to bring Nvidia's market cap up to $15 trillion.

Many investors will find these numbers hard to believe, and this is undoubtedly a bull-case scenario based on optimistic projections from CEO Jensen Huang and his team. However, recall that just three years before Nvidia became the world's first $4 trillion company, it was worth about $300 billion.

And even if the actual market opportunity comes in below Nvidia's outlook, the rapid growth of AI development should still be enough to support the stock's market-beating track record, making it a buy regardless.

Keithen Drury has positions in Alphabet, Amazon, Meta Platforms, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Renewed interest in nuclear energy has Centrus stock has soaring.

Centrus Energy (LEU -2.19%) has been one of several nuclear energy stocks that have crushed the market in 2025. Compared to the S&P 500's impressive 13% gain so far this year, Centrus' stock is up about 295%  in 2025 at the time of writing -- and over 450% year over year.

At that yearly gain, you'd be forgiven if you thought Centrus was training large language models (LLMs) instead of enriching uranium. And yet its growth potential does have an indirect connection with artificial intelligence (AI) in that its fuel could help power the data centers behind the boom.

With the first American-owned enrichment plant to start production in decades, Centrus finds itself at the center of an industry that hasn't seen this much interest since the 1970s. But does that make this growth stock a no-brainer buy today?

Ground floor side view of the HALEU cascade. Image source: Centrus Energy.

A unique position in nuclear fuel
Centrus operates two main businesses. The first is supplying low-enriched uranium (LEU) for today's reactors. And the second is providing technical services, including a Department of Defense (DOE) contract, to produce high-assay low-enriched uranium (HALEU) for advanced reactors.

Of the two, the HALEU production likely offers more growth opportunity long-term. That's because many next-generation reactors -- like small modular reactors (SMR) -- are increasingly being designed to run on this fuel.

In Piketon, Ohio, it runs the only U.S.-owned enrichment facility licensed to make HALEU. Emphasis there on only: Centrus currently holds the only license from the Nuclear Regulatory Commission to enrich uranium above 5%. If HALEU does end up becoming the preferred fuel for future reactors, Centrus could have a first-mover advantage in the U.S. for producing it.

The first U.S. supplier of HALEU -- but with a Russian connection
But don't overlook the last part of that sentence. Although no other U.S. company is licensed to produce HALEU, there are several companies producing it worldwide, some at a much larger scale than Centrus.

One is a Russian company, Tenex, a subsidiary of the state-owned Rosatom. The funny thing about Tenex: It has a supply contract with Centrus, meaning that some of Centrus' LEU -- which it sells to reactors in the U.S. -- comes from Russian supplies. Any geopolitical risk -- or a refusal on the part of Tenex to continue supplying Centrus -- could hurt the company's ability to meet obligations.

That hasn't happened yet, however, and Centrus is likely aware of this dependence. But until it can achieve self-sufficiency in production, the Russian link to LEU remains an uncomfortable fact, especially since Tenex is also the world's go-to for HALEU.

The balance sheet and the market's bet
Usually, when I write about advanced nuclear stocks, the phrase "pre-revenue" always finds a place near "balance sheet." In this way, Centrus is ahead of the pack in that it's not only selling something (fuel) but it's actually profitable.

In the second quarter of 2025, it reported net income of $28.9 million, a slight decrease from $30.6 million a year ago. What stood out, however, was its gross profit of about $54 million -- an increase of 48% from last year -- which shows a stronger margin even as revenue declined.

LEU Net Income (Quarterly) data by YCharts

The company also ended the quarter with a hefty consolidated cash balance of $833 million and a backlog of $3.6 billion that extends to 2040.

Is now the best time to buy Centrus?
Centrus offers a rare, U.S.-based play on nuclear fuel independence at a time when governments are rethinking energy. And yet it's not an obvious buy, at least for those who want to stay away from volatility.

Bulls will point to a few major tailwinds at Centrus' back.

The first is policy. In May 2025, President Donald Trump signed a flurry of executive orders aimed at boosting the country's nuclear energy capacity, including calls for a stronger domestic supply chain of nuclear fuel. That puts Centrus in a strong position to benefit from government funding.

Meanwhile, international interest, like Centrus' recent memorandum of understanding with Korea Hydro & Nuclear Power, could be stirring, especially as concerns rise over Russia's dominance of the global nuclear fuel market.

But even the bulls have to acknowledge that Centrus, though it has support, doesn't have the industrial capacity to produce enriched uranium at scale. Until expansion efforts at its Piketon plant are complete, or new capacity is turned online, Centrus will remain pretty supply-constrained for now.

Investors interested in Centrus' stock should also take note of its rich valuation. At today's price, the stock trades at 76 times forward earnings, which is several times higher than the energy sector writ large (about 16).

Clearly, investors are expecting growth. Whether or not they get it will depend on Centrus' ability to scale enrichment capacity.

Steven Porrello has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

A robust pipeline of experimental and recently launched drugs could make the next several years exciting ones to be a Pfizer shareholder.

It's been a rough few years to be a Pfizer (PFE 0.64%) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine, Comirnaty, racked up $36.8 billion in sales.

In the first half of 2025, Comirnaty sales came in at just $945 million. Sales of Paxlovid, an antiviral treatment for COVID-19, fell 60% year over year to $918 million. Despite sinking demand for Comirnaty and Paxlovid, Pfizer's post-COVID future looks bright.

Image source: Getty Images.

In 2023, Pfizer plowed $43 billion into Seagen, a cancer drug developer with a robust pipeline. Now, the company markets several Seagen treatments, including Padcev, which has become a popular first-line option for bladder cancer patients. In the second quarter, Padcev sales jumped 38% higher year over year to an annualized $2.2 billion.

Padcev sales could keep growing by leaps and bounds thanks to recent results from an adjuvant study. At the first interim analysis, a clinical trial showed that giving patients long-term treatment with Padcev before and after tumor removal surgery significantly increased their odds of long-term survival.

Padcev is just one of several acquired cancer therapies likely to generate growing sales down the road. For example, Elrexfio earned approval in 2023 to treat multiple myeloma patients who failed four previous lines of treatment.

In a trial with newly diagnosed patients, Elrexfio shrank tumors for 97% of those treated. A move to treat new patients who tend to stay on treatment for a long time could drive peak sales above $5 billion annually. With Padcev, Elrexfio, and an experimental obesity treatment still in development, the coming decade could be a great one for patient investors.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

These companies are going after multitrillion-dollar industries.

Growth stocks make it fairly easy for anyone to build wealth in the stock market. Focusing on the companies that are innovating and disrupting large industries can help you find the right stocks that deliver explosive gains.

Here are two growth stocks that have already delivered significant gains for investors with room to run over the long term.

Image source: Getty Images.

1. Shopify
Shopify (SHOP -2.25%) has truly been a monster stock. Investors who bought shares shortly after its initial public offering in 2015 would be up over 4,000% today, and it's up over 400% since the market bottomed out in 2022.

These returns ultimately reflect the value Shopify offers business owners. For a relatively low subscription cost, merchants can set up an online store, accept payments, and have access to artificial intelligence (AI) tools that automate tasks.

Shopify has ample room to grow. The total value of all transactions completed with a Shopify merchant was $88 billion last quarter, or an annual run rate of $352 billion. Even though Shopify continues to grow its business at high double-digit rates, its annual GMV is still a small fraction of the $6 trillion global e-commerce market.

There are two important facts that make the stock a good investment.

Shopify is leveraging the power of AI to fuel product development and drive more revenue growth without increasing costs. It has benefited from this by growing its free cash flow by over 850% over the last three years while lowering its headcount.
Shopify's merchants are growing faster than the broader e-commerce market. This reflects a strong competitive moat. Shopify makes most of its revenue from payments and other merchant solutions, which means it's only as successful as the businesses that use it. With merchants in its network outperforming the e-commerce market, it shows that Shopify is delivering on its promise to help merchants succeed in a competitive e-commerce landscape.

The stock should be a rewarding investment for investors buying today. There are a lot of opportunities to sign up more businesses worldwide, and Shopify's opportunity to use AI within its own product development efforts could yield significant gains on the bottom line that aren't reflected in the stock's valuation.

Image source: Getty Images.

2. Duolingo
Duolingo (DUOL 4.29%) stock is up 235% over the last three years, and that's after a recent pullback from its 52-week high. The stock's performance reflects the consistent growth in the language learning app's daily active users (DAUs) and financial results. This company is on a mission to disrupt the education market, which Morgan Stanley expects to be worth $8 trillion by 2030.

Duolingo is seeing great traction in gaining more users. DAUs grew 40% year over year in Q2 to nearly 48 million. There is demand for learning, and while there are a lot of options out there, Duolingo has created a fun and engaging experience that is starting to build a strong brand.

Duolingo started with its language learning course, but it has expanded to chess and math, and it will continue to expand to more subjects. Every new course it offers expands its revenue potential, which it earns through subscriptions to Super Duolingo and Duolingo Max, as well as advertising and in-app purchases.

The reason Duolingo could disrupt education is that it is delivering a personalized learning experience using AI. Every user who engages with the app is providing valuable data to Duolingo that it uses to constantly tweak the experience to help users learn and stay engaged.

As the AI models become smarter, Duolingo can efficiently generate new content fairly quickly without significantly increasing costs. This could benefit Duolingo's profitability, similar to Shopify. Over the last three years, the company's trailing-12-month revenue has increased 161% to $885 million, while free cash flow has exploded 900% to $321 million.

Of course, the company's growth is a byproduct of delivering on its promise to help people learn something. This is evident by the faster rate of growth in daily active users over monthly active users, indicating that more of its user base is using the app every day. It's clear Duolingo is in the early stages of building a competitive moat and potentially upending a multitrillion-dollar industry.

John Ballard has positions in Duolingo. The Motley Fool has positions in and recommends Shopify. The Motley Fool recommends Duolingo. The Motley Fool has a disclosure policy.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.

So What: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=19024 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On August 7, 2025, before the market opened, the company issued a press release entitled "Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps." The release stated that Tandem Diabetes had "announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery."

On this news, Tandem Diabetes' stock fell 19.9% on August 7, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

The Bureau of Labor Statistics is scheduled to release the jobs report on Friday—but that could be jeopardized if the Congress doesn't reach a funding agreement by Tuesday night.

SAXONBURG, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, announced today that it will showcase its latest innovations in next-generation optical communications at ECOC 2025, taking place September 29-October 1 at the Bella Center in Copenhagen, Denmark (Booth #C3124). Coherent thought leaders will contribute to the Market Focus program through panels, workshops, and round table sessions.

“ECOC is the European premier global stage for showcasing innovation in datacenters and communications, and we’re excited to demonstrate how in Coherent we are shaping next-gen optical networking. We are excited to be at ECOC showcasing our innovation, our portfolio and contributing to thought leadership. Through our advanced technologies, close industry collaborations, and broad portfolio, we are helping customers build the networks of tomorrow,” said Dr. Sanjai Parthasarathi, Chief Marketing Officer at Coherent.”

RECENT PRODUCT ANNOUNCEMENTS:

2D VCSEL Array
Delivering power-efficient, compact optical links optimized for short-reach AI/ML datacenter interconnects, this 1.6T (32x50G) array is designed for scale-up networks, enabling low latency, cost efficiency, and seamless migration to Near-Packaged and Co-Packaged Optics.

100G ZR for Single-Fiber Operation
The industry’s first dual-laser QSFP28 DCO module for single-fiber, bi-directional applications delivers 10x capacity upgrades on existing 10G infrastructure. Powered by the low-power Steelerton™ DSP, it enables flexible, scalable, and cost-efficient optical access for next-generation connectivity.

400mW CW Laser
Built on the proven BH DFB platform, the new 400 mW continuous-wave (CW) laser delivers stable high output, ultra-low noise, and narrow linewidths in a compact chip-on-carrier format. Engineered for next-generation co-packaged optics (CPO) and silicon photonics, it enables breakthrough performance in optical interconnects.

High precision glass molded 2D lens array
Leveraging Coherent’s state-of-the-art glass molding platform, the new 2D lens array enables wafer-level manufacturing that delivers unprecedented uniformity, higher bandwidth, and lower cost in multi-channel optical transmission. It is ideal for use in optical circuit switching, high-precision coupling, advanced imaging, sensing, and AR/VR devices.

Quad-Channel IC Family
Coherent’s new quad-channel ICs include silicon photonics Mach-Zehnder drivers for 800G/1.6T pluggables and a chipset for 400G ZR/ZR+ links. Delivering industry-leading performance with lower power consumption, these fiber-optic ASICs enable faster, more efficient optical transceivers for cloud, AI, and telecom applications.

Wire Grid Polarizer for Datacom Transceivers
Coherent’s next-generation meta-wire based WGP achieves a 50 dB extinction ratio and 98.5% efficiency with dual-sided AR coating. Compact, power-resilient, and cost-effective, it enables high-speed datacom transceivers and dynamic datacenter architectures, supporting the growing demands of AI-ready optical networks.

TECHNOLOGY AND PRODUCT DEMONSTRATIONS:

Scalable Quantum-Safe Network Demo
This proof-of-concept showcases a quantum-safe networking solution that can be deployed efficiently and at scale without disrupting existing infrastructure. The demo integrates CUbIQ’s modular CV-QKD transceivers in a QSFP-28 pluggable form factor with Coherent’s high-performance 400G ZR QSFP-DD DCO optical transceivers and a PTX Series routing platform, delivering high-speed, energy-efficient quantum key distribution over existing fiber networks. Supported by Liberty Global’s deployment insights, the demo illustrates a path for telecom operators to future-proof their networks for secure communications.

100G QSFP28-DCO ZR Dual Laser
This demo showcases Coherent’s QSFP28 dual-laser transceiver with separate Tx/Rx tuning, delivering up to 300 km reach with <7W power dissipation. Designed for single-fiber, bi-directional links, it enables 10x capacity gains, doubles fiber inventory, and supports applications from wireless towers to cable TV network expansion.

100G QSFP28-DCO ZR active ingress/egress latency control
This demo features Coherent’s QSFP28 module with active ingress/egress latency control, enabling ultra-low latency variation and Class C Precision Time Protocol accuracy. With synchronization precision down to ±10 ns at system level, it supports demanding applications such as telecom networks, industrial automation, and financial trading.

External Laser Source Module for CPO
This demo showcases Coherent’s ELSFP compliant module integrating eight high-power 1310 nm lasers, with exceptional wavelength accuracy and linewidth control. Ideal for co-packaged optics (CPO) and DR/FR applications, it provides a reliable, compact external laser source for next-generation optical systems.

1.6T 2xFR4 with 6km reach
Coherent’s 1.6T 2x800G-FR4 transceiver extends the reach from 2–3 km to 6 km, delivering excellent BER. With a miniature dispersion compensation component inside, this transceiver module demonstrates that IMDD links can support reaches of up to 6 km.

300G/lane link
As a milestone towards enabling speeds higher than 200G/lane, Coherent is demonstrating a 300G/lane link. It uses Coherent's Differential EML.

Multi-rail technology
This demo highlights Coherent’s multi-rail technology with resource pooling, designed to deliver four times the capacity over existing system reach using deployed fiber. With sub-linear increases in power and volume, a 20-year reliability target, and compliance with safety standards, it enables efficient, scalable growth for future optical networks.

TEST AND MEASUREMENT

WaveAnalyzer 200B
The WaveAnalyzer 200B is the only portable, battery-powered analyzer capable of up to two full sweeps per second across the entire Super C-Band with 650 MHz resolution. It gives fast, precise insight into complex, high-capacity networks, making it ideal for lab research, system installation, and field maintenance.

WaveShaper 500B/X
The WaveShaper 500B/X delivers unmatched flexibility for production testing of optical transceivers, shaping signal attenuation across the Super C- and L-Bands with over 12.4 THz coverage. With sub-100 ms loading time, it enables high-throughput manufacturing by accelerating testing and reducing cost.

WORKSHOP:

“Which Modulator Technology Will Dominate In Next-Generation Transceivers?
Speaker: Po Dong, VP, Silicon Photonics Technology
Topic: SiPho vs. InP for high-volume transceivers
Sunday, Sep. 28th, 9.00 am -12.30 pm, Auditorium 12

MARKET FOCUS

Topic: Modules/sub systems
Speaker: Anna Tatarczak, Distinguished Member of Technical Staff
Title: How 400G Lanes Will Reshape the Next-Gen Datacenter Market
Monday, Sep. 29th, 11:20-11:35 am

Topic: Modules/sub systems
Speaker: Julie Eng, CTO
Title: Advances in optical components, transceivers, and co-packaged optics
Monday, Sep. 29th, 1:40-1:55 pm

Topic: Modules/sub systems
Chair: Sanjai Parthasarathi, CMO

Fireside chat with Jose Pozo
Speaker: Sanjai Parthasarathi, CMO
Title: Can We Deliver What the Market Needs? Manufacturing Challenges of Co-Packaged Optics
Monday, Sep. 29th, 4:00-4:30 pm

Panel: 1.6T deployment status and outlook for 100T switching
Speaker: Sanjai Parthasarathi, CMO
Tuesday, Sep. 30th, 3:40-4:30 pm

Topic: Networking/systems/Service provider
Speaker: Ian McClean, Senior Product Manager
Title: Enabling sublinear capacity scaling through multi-rail photonic technology
Monday, Sep. 29th, 11:00-11:15 am

About Coherent 

Coherent is the global photonics leader. We harness photons to drive innovation. Industry leaders in the datacenter, communications, and industrial markets rely on Coherent’s world-leading technology to fuel their own innovation and growth.

Founded in 1971 and operating in more than 20 countries, Coherent brings the industry’s broadest, deepest technology stack; unmatched supply chain resilience; and global scale to help its customers solve their toughest technology challenges. Visit us at coherent.com.

Media Contact: 

[email protected] 

The upcoming commercialization of the Neutron is vital for Rocket Lab's continued progress.

The next 12 months are crucial for Rocket Lab (RKLB -0.86%). After years of consistent growth with its small Electron rocket system, the company is set to test and debut a new rocket type called the Neutron later this year to compete directly with the dominant SpaceX. As an unprofitable mover in the space economy, Rocket Lab is banking on the Neutron to help bring the company to a larger scale financially and finally turn a profit. Plus, it could be the springboard for the company's long-term satellite constellation plans.

By the end of this year, Rocket Lab is scheduled to perform a test flight with the Neutron. This is the final step before commercialization and revenue generation from launch contracts. Does that mean you should buy Rocket Lab stock before the Neutron takes flight?

Larger payloads, larger revenues
When launching a rocket, there are three important items for a commercial customer: cost, payload, and reliability (meaning the rocket is not likely to blow up). Rocket Lab's Electron rocket -- its only commercialized rocket today -- has a small payload of just 300 kilograms versus 13,000 for the workhorse Falcon 9 from SpaceX.

This has allowed it to earn niche missions to prove its reliability, but has kept Rocket Lab out of any large payload contracts. If a company wants to launch hundreds of large satellites into orbit, it will go to SpaceX, as it would be inefficient and time-consuming to use many different Electron missions.

Neutron plans to level the playing field. It will have a payload capacity similar to the Falcon 9, which will expand Rocket Lab's total addressable market for launch contracts. SpaceX has been a virtual monopoly in large rocket launches for years now, even though it competes directly with its customers through its Starlink satellite internet service. Rocket Lab can become the second player in the sector, potentially convincing customers to switch from SpaceX.

The average Electron mission costs $7.5 million for a Rocket Lab customer compared to a reported average of $67 million for every Falcon 9 mission. Rocket Lab's revenue over the last 12 months was just $500 million, meaning just a few Neutron launches a year could significantly boost the company's revenue. If it launches just 10 times at the same cost as the Falcon 9, that would more than double its current consolidated revenue.

Image source: Getty Images.

Building its own constellation
Rocket Lab is not just a launch provider. It also builds space systems for customers, which include things such as satellites, photovoltaics, and even spacecraft. This is a larger revenue generator than launch services, with $97.9 million in revenue last quarter compared to $46.6 million for rocket launches from the Electron.

Commercializing the Neutron may help rocket launch revenue surpass space systems in the interim. However, over the long term, its effect may be more felt in Rocket Lab's long-term plan for providing its own services from space to third parties. This has been compared to SpaceX's Starlink internet service, although it is unclear if Rocket Lab will be selling internet or some other service from its proposed satellite constellation. Either way, its Neutron rocket will enable the company to easily get enough satellites into orbit.

RKLB PS Ratio data by YCharts. PS = price-to-sales.

Should you buy Rocket Lab stock?
Rocket Lab's space economy business has loads of potential. Unfortunately, this potential is now priced into its soaring stock. At a share price of $50, Rocket Lab is up over 10x in the past few years and now has a market cap of $24 billion. It's going to further dilute shareholders with a new at-the-money stock offering of $750 million that it will use to fund more investments into the Neutron, manufacturing, and launch facilities.

A market value of $24 billion versus $500 million in trailing revenue gives Rocket Lab a price-to-sales (P/S) ratio of 49. That's a wildly expensive multiple, even if you believe Rocket Lab is about to start generating billions of dollars in annual revenue sometime in the near future. Neutron commercialization may bring about a step change in growth, but that step change seems to already be priced into the stock.

Avoid buying Rocket Lab stock at this expensive P/S ratio. Keep it on the watchlist for now and buy on any future dips instead.

Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy.

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical Response (HiSCR) 75 as primary endpoint at week 16Data was analyzed, as per protocol and in accordance with regulatory agency feedback, using a composite strategy as the primary analysis and a treatment policy strategy to test the robustness of the results: difference between the two methods relates to the statistical handling of intercurrent eventsIn the combined VELA program, patients treated with sonelokimab experienced a clinically meaningful and statistically significant improvement across all primary and key secondary endpoints using both pre-specified strategies (p<0.001)In VELA-1, sonelokimab achieved statistical significance for all primary and key secondary endpoints using both pre-specified strategies (HiSCR75, delta to placebo of 17%, p<0.001)In VELA-2, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy (HiSCR75, delta to placebo of 9%, p=0.053)The pre-specified treatment policy strategy provides for the analysis of data irrespective of intercurrent events; using this analysis, a statistically significant HiSCR75 at week 16 in VELA-1 and VELA-2 was achieved with sonelokimab (35% and 36%, respectively) vs placebo (18% and 26%, respectively); clinically meaningful and statistically significant benefit was also observed for all key secondary endpoints (Table 2)Sonelokimab continued to show a favourable safety profile with no new safety signals detected, including an absence of key events of interest such as suicidal ideation and behavior VELA progresses to its pre-specified week 52 readout and the Company will now seek to confirm the path to registration in HS with the appropriate regulatory authorities Other clinical studies with sonelokimab, including the Phase 3 VELA-TEEN trial in adolescent HS, the Phase 3 IZAR program and the Phase 2 P-OLARIS trial in psoriatic arthritis (PsA), the Phase 2 LEDA trial in palmoplantar pustulosis (PPP), and the Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA), continue as planned and are expected to support a catalyst-rich roadmapThe Company will hold a webcast on Monday, September 29 at 2pm CET / 8am EDT (link below) ZUG, Switzerland, September 28, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the week 16 results of the Phase 3 VELA-1 and VELA-2 trials of its registrational global program in patients with moderate-to-severe hidradenitis suppurativa (HS).

The VELA program used the higher clinical response level of HS Clinical Response (HiSCR) 75 as the primary endpoint, which defines a response as an at least 75% reduction in abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count. Key secondary endpoints included the percentage of participants achieving HiSCR50 and the percentage of patients achieving a Dermatology Quality of Life Index (DLQI) total score reduction of >4 (minimal clinically important difference), among participants with a baseline DLQI >4, as well as other scores that reflect the evolving needs of HS patients, treating physicians and regulators. These included the percentage of participants achieving at least a 55% reduction in the International HS Severity Scoring System (IHS4-55), the percentage of participants achieving at least a 3 point improvement from baseline in the worst pain Numerical Rating Scale (NRS) among participants with a baseline score of at least 3 points, and the change from baseline in the HS-specific Quality of Life score (HiSQOL). A total of 838 patients were enrolled across both trials. The trials were identical in design comparing a single 120mg dose of sonelokimab to placebo with HiSCR75 reading out at week 16. From week 16, all patients receive the 120mg dose of sonelokimab through to 48 weeks, with a last assessment at week 52, followed by an open-label extension for up to two years. The Phase 3 program used a protocol design consistent with the Phase 2 MIRA trial, which identified the optimal dose of sonelokimab for HS. The VELA protocols and statistical analysis plans were prepared in accordance with regulatory agency advice and include two analysis strategies. The composite strategy for the VELA trials is the primary statistical analysis. The protocol specifies the treatment policy strategy as the alternative method of handling intercurrent events to test the robustness of the VELA data. Data in this press release is presented using the aforementioned analysis strategies, as indicated throughout. The baseline characteristics for VELA-1 and VELA-2 are shown in Table 1.

TABLE 1

Baseline CharacteristicsTrials VELA 1VELA 2 Placebo
(n=138)SLK
(n=283)Placebo
(n=141)SLK
(n=276)Age [years], mean 36.137.238.037.2Female, % 62.361.549.653.6Race, % 
       White 
       Black or African American 76.1 
15.277.7 
12.085.1 
10.681.5 
9.4BMI, mean 33.633.532.733.0Current smoker, % 41.343.856.051.8Hurley Stage, % 
       II 
       III 63.8 
36.64.0 
36.067.4 
32.663.0 
37.0Years since diagnosis, mean 8.48.17.77.5Lesions, mean 
       AN count 
       DT count 13.3 
2.813.5 
3.213.8 
3.514.5 
3.9DLQI Total, mean 11.811.711.312.6HiSQOL Total, mean 27.626.523.828.0Patient Global Assessment of Skin Pain NRS, mean 4.94.75.04.9Prior biologic use, % 15.915.522.019.6Concomitant antibiotics, % 8.76.77.810.5 In the combined Phase 3 VELA program, all endpoints reached statistical significance with p-values below 0.001, including lesion counts and patient reported outcomes (PROs), as per Table 2. Sonelokimab demonstrated the expected profile of response over time, with statistically significant HiSCR75 for both studies achieved as early as week 4 (Table 3). A preliminary analysis suggests that responses continue to improve beyond week 16 and that placebo patients crossing over at week 16 achieve similar responses to those originally randomized to the sonelokimab 120mg arm, as of week 20 (pre-specified analysis, data not shown).

Using the treatment policy strategy as per protocol, both VELA-1 and VELA-2 showed a statistically significant increase in the percentage of participants achieving HiSCR75 at week 16 and provided a clinically meaningful benefit (Table 2). Response rates for sonelokimab 120mg were consistent between the two trials, with 34.8% and 35.9% of patients in VELA-1 and VELA-2 achieving HiSCR75 at week 16, respectively. The placebo response rate in VELA-1 of 17.5% at week 16 was within the historical Phase 3 range of 13% to 18%. The placebo response rate in VELA-2 of 25.6% at week 16 was higher than expected.

Both VELA-1 and VELA-2 achieved statistical significance for all key secondary endpoints (Table 2). This includes other lesion count based endpoints (HiSCR50 and IHS4-55). It also includes relevant PROs in HS. Around 30% of patients experienced a marked reduction of pain, as measured by an at least 3-point improvement in the worst pain NRS, in both VELA-1 and VELA-2 (p≤0.002). Sonelokimab showed a significant improvement of HiSQOL score at week 16 (p<0.001), which was consistent between VELA-1 and VELA-2. Almost 60% of patients achieved a meaningful (4 points or more) improvement of DLQI, an approximately 20 percentage-point benefit over placebo (p≤0.001).

Overall, the week 16 endpoint results using the treatment policy strategy were as follows:

TABLE 2

EndpointTrialClassTypeScoreVELA combinedVELA-1VELA-2Placebo (n=279)SLK 120mg (n=559)p-valuePlacebo (n=138)SLK 120mg (n=283)p-valuePlacebo (n=141)SLK 120mg (n=276)p-valuePrimaryLesion countHiSCR75 (%)21.635.4<0.00117.534.8<0.00125.635.90.033Key secondaryHiSCR50 (%)36.755.1<0.00130.351.6<0.00143.058.70.003IHS4-55 (%)39.455.7<0.00134.254.4<0.00144.756.90.021Patient-reported outcome (PRO)Pain NRS 3pt (%)13.929.1<0.00112.728.40.00114.929.80.002HiSQOL (CFB)-3.5-9.1<0.001-3.8-9.4<0.001-3.5-9.0<0.001DLQI (MCID, %)38.358.6<0.00137.859.0<0.00139.058.10.001 Note 1: ITT, pre-specified treatment policy strategy
Note 2: Across the VELA program all deltas to placebo vary between treatment policy and composite strategy by less than 1.5 percentage points (HiSQOL varies by less than 0.5 points)
Note 3: For VELA-1 and VELA-2, using composite strategy, all primary and key secondary endpoints achieved p<0.025 except for VELA-2 primary endpoint (HiSCR75, p=0.053); control for multiple testing was only performed within the composite strategy testing for VELA-1 and VELA-2 individually. Statistical significance refers to analyses where p<0.05, in both multiplicity and non-multiplicity controlled strategies
Note 4: “Pain NRS 3pt “ refers to Worst Pain NRS reduction of at least 3 points; “CFB” refers to mean change from baseline; “MCID” refers to minimally clinically important difference which reflects a reduction of at least 4 points in the score

The percentage of participants achieving HS Clinical Response (HiSCR) 75 at different timepoints was as follows:

TABLE 3

TrialArmTime (weeks)02481216VELA combinedPlacebo (n=279)06.17.117.117.821.6SLK 120mg (n=559)08.819.230.335.835.4Delta02.712.113.118.013.8p-value 0.157<0.001<0.001<0.001<0.001VELA-1Placebo (n=138)07.36.514.115.817.5SLK 120mg (n=283)08.920.529.533.834.8Delta01.614.015.418.017.3p-value 0.570<0.001<0.001<0.001<0.001VELA-2Placebo (n=141)05.07.620.119.825.6SLK 120mg (n=276)08.618.031.137.935.9Delta03.710.411.118.110.3p-value 0.1450.0020.011<0.0010.033 Note 1: ITT, pre-specified treatment policy strategy (time points other than week 16 were pre-specified Other secondary endpoints)
Note 2: Multiplicity control was only applied for testing of the primary and key secondary endpoints at week 16 by composite strategy in VELA-1 and VELA-2 individually. Statistical significance refers to analyses where p<0.05, in both multiplicity and non-multiplicity controlled strategies

The safety profile of sonelokimab was consistent with previously reported studies with no new safety signals observed. This includes the absence of new signals in key events of interest with IL-17A and F therapies: Suicidal Ideation and Behavior, hepatic events, IBD and non-infectious diarrhea, MACE and Eczema and Dermatitis (Table 4).

TABLE 4

Participants with event, n (%) Placebo(n=279)

 Sonelokimab 120 mg(n=559)

 Any TEAE 155 (55.6) 376 (67.3)       Any serious TEAE 5 (1.8) 14 (2.5)       Any TEAE leading to treatment discontinuation 4 (1.4) 16 (2.9)       Most frequent TEAEs1                  Nasopharyngitis 28 (10.0) 48 (8.6)              Headache 14 (5.0) 27 (4.8)              Upper respiratory tract infection 21 (7.5) 24 (4.3)       Safety topics of interest                  IBD2 0 0              Diarrhea (non-infectious)3 1 (0.4) 2 (0.4)              Oral candidiasis4 1 (0.4) 41 (7.3)              Serious hypersensitivity 0 0              Dermatitis & Eczema5 7 (2.5) 20 (3.6)              Serious infections 2(0.7) 4 (0.7)              SI/B6 0 0              Hepatic events7 3 (1.1) 1 (0.2)              MACE8 0 0  1 Most frequent TEAEs excluding safety topics of interest (as presented separately in this table) and one TEAEs to maintain blinding of the ongoing VELA studies 2 AESI, events in adjudication; 3 AESI; 4 there were three cases of oesophageal candida and two cases of oropharyngeal candida on SLK; 5 PTs eczema and dermatitis; 6 Reported adverse events, 7 Hepatic events (all hepatic AEs and laboratory investigations in adjudication to possible DILI); 8 Events in adjudication

Overall, the Company believes that sonelokimab continues to show a favorable safety profile, with no new safety signals detected and a competitive outlook. The VELA program is conducted using a convenient sub-cutaneous dosing scheme with 1ml volume delivered every other week to week 6 in the induction phase (4 injections), and monthly from week 8 for maintenance, with no up-titration. This profile is matched by improvements of HS lesions, including draining tunnels, as well as in all key Patient Reported Outcomes (PROs), such as quality-of-life and pain scores, that are meaningful for HS patients and their treating physicians.

   
Prof. Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: “We are encouraged by the results of VELA-1, which follow the expected performance of sonelokimab in all the important metrics for patients and treating physicians. The higher-than-expected placebo response rate in VELA-2 is disappointing but we are encouraged by the consistent performance of sonelokimab arms across all endpoints in both studies. We are pleased to see a favorable safety profile consistent with previous studies, with no new safety signals. We believe that this, together with the convenient dosing, the efficacy data in the lesion-based metrics and the patient reported outcomes, shows the potential for a promising profile of sonelokimab in HS. Patients with HS are in desperate need of new treatment options and we remain committed to our path forward in HS.”

These interim results will now be discussed with the appropriate regulators, including the analytical strategies considering the higher-than-expected placebo response rate in VELA-2 at week 16 and path to submission of a Biologics License Application.

The Company continues to progress with the development of its Nanobody® sonelokimab across a portfolio of indications, including:

Q4 2025: Primary endpoint readout of the Phase 2 LEDA trial in PPPQ1 2026: Primary endpoint readout of the Phase 2 S-OLARIS trial in axSpAQ2 2026: 52 weeks data of the VELA-1 and VELA-2 trials in HSH1 2026: Primary endpoint readout of Phase 3 VELA-TEEN trial in adolescent HSH1 2026: Primary endpoint readout of Phase 3 IZAR program in PsA The Company will hold a webcast on Monday 29th of September at 2pm CET / 8am EDT. Link to the webcast, a replay of it and the presentation document will be made available at https://ir.moonlaketx.com.

Sonelokimab is not yet approved for use in any indication.

-Ends-

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The Company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.

About Nanobodies®

Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations.

The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.

About Sonelokimab

Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three variable regions of heavy-chain-only antibodies domains (VHHs) covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.

Sonelokimab is being assessed in two lead indications, hidradenitis suppurative (HS) and psoriatic arthritis (PsA), and the Company is pursuing other indications in dermatology and rheumatology, including adolescent HS, palmo-plantar pustulosis (PPP) and axial spondyloarthritis (axSpA).

For adults with HS, sonelokimab is being assessed in the Phase 3 trials, VELA-1 and VELA-2, following the successful outcome of MoonLake’s end-of-Phase 2 interactions with the FDA and as well as positive feedback from its interactions with the EMA announced in February 2024. In June 2023, topline results of the MIRA trial (NCT05322473) at 12 weeks showed that the trial met its primary endpoint, the Hidradenitis Suppurativa Clinical Response (HiSCR) 75, which is a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials, setting a landmark milestone. In October 2023, the full dataset from the MIRA trial at 24 weeks showed that maintenance treatment with sonelokimab led to further improvements in HiSCR75 response rates and other high threshold clinical and patient relevant outcomes. The safety profile of sonelokimab in the MIRA trial was consistent with previous trials with no new safety signals detected.

Sonelokimab is currently undergoing evaluation in the VELA-TEEN Phase 3 trial, which is the first clinical study specifically focused on adolescent patients with moderate-to-severe HS.

For PsA, sonelokimab is being assessed in the Phase 3 trials, IZAR-1 and IZAR-2, following the announcement in March 2024 of the full dataset from the global Phase 2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody® sonelokimab over 24 weeks in patients with active PsA. Significant improvements were observed across all key outcomes, including approximately 60% of patients treated with sonelokimab achieving an American College of Rheumatology (ACR) 50 response and Minimal Disease Activity (MDA) at week 24. This followed the positive top-line results in November 2023, where the trial met its primary endpoint with a statistically significant greater proportion of patients treated with either sonelokimab 60mg or 120mg (with induction) achieving an ACR50 response compared to those on placebo at week 12. All key secondary endpoints in the trial were met for the 60mg and 120mg doses with induction. The safety profile of sonelokimab in the ARGO trial was consistent with previous trials with no new safety signals detected.

Sonelokimab is also being assessed in the Phase 2 LEDA trial, which is ongoing for PPP, a debilitating inflammatory skin condition affecting a significant number of patients.

Additionally, Sonelokimab is being assessed in the ongoing Phase 2 S-OLARIS trial for active axSpA. The trial features an innovative design complementing traditional clinical outcomes with cellular imaging techniques.

Sonelokimab has also been assessed in a randomized, placebo-controlled third-party Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis. High threshold clinical responses (Investigator’s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index 90/100) were observed in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).

In an earlier third-party Phase 1 trial in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196–203).

About the VELA program

The Phase 3 VELA program has enrolled over 800 patients across VELA-1 and VELA-2. Both global, randomized, double-blind, placebo-controlled trials are identical in design evaluating the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in adult patients with active moderate-to-severe hidradenitis suppurativa. Similar to the design of the landmark Phase 2 MIRA trial, the primary endpoint is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75, defined as a ≥75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trials will also evaluate a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total reduction of ≥4, the proportion of patients achieving at least 50% reduction from baseline in Numerical Rating Scale (NRS50) in the Patient’s Global Assessment of Skin Pain (PGA Skin Pain) and complete resolution of Draining Tunnels (DT100). The VELA protocols and statistical analysis plans were prepared in accordance with regulatory agency advice and include two analysis strategies. The composite strategy for the VELA trials (also referred to as the primary estimand) is the primary statistical analysis. The protocol specifies the treatment policy strategy as the alternative method of handling intercurrent events to test the robustness of the VELA data. Data in this press release is presented using the aforementioned analysis strategies, as indicated throughout. Further details are available under NCT06411379 and NCT06411899 at ClinicalTrials.gov.

About the VELA-TEEN trial

The Phase 3 VELA-TEEN trial is an open-label, single-arm trial designed to evaluate sonelokimab 120mg administered subcutaneously once every two weeks (Q2W) until week six and once every four weeks (Q4W) from week eight onwards. The trial aims to enroll 30-40 adolescents, aged 12-17, with moderate-to-severe hidradenitis suppurativa, from U.S. sites experienced in clinical trials and pediatric dermatology. The primary trial phase will be 24 weeks with a primary endpoint evaluating the pharmacokinetics, safety, and tolerability of sonelokimab. VELA-TEEN will also evaluate several secondary endpoints, including the proportion of patients achieving the higher clinical response measure of the Hidradenitis Suppurativa Clinical Response Score (HiSCR) 75, in addition to HiSCR50. Other outcomes are the change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4), which includes the quantitative measure of draining tunnels, and the proportion of patients achieving a meaningful reduction of the Children’s Dermatology Life Quality Index (CDLQI) and the Patients Global Assessment of Skin Pain (PGA Skin Pain). Further details are available under NCT06768671 at ClinicalTrials.gov.

About Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result in irreversible tissue destruction and scarring. The disease affects an estimated 2% of the population, with three times more females affected than males. Real-world data in the US indicates that at least 2 million unique patients have been diagnosed with and treated for HS between 2016 and 2023 alone, highlighting a significant unmet need and impact on healthcare systems, and a market opportunity projected to reach $15bn by 2035. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with a higher morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17F-mediated inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity.

About the IZAR Program

IZAR-1 (NCT06641076) and IZAR-2 (NCT06641089) are global, randomized, double-blind, placebo-controlled Phase 3 trials designed to evaluate the efficacy and safety of sonelokimab compared with placebo in a total of approximately 1,500 adults with active psoriatic arthritis (PsA), with a primary endpoint of superiority to placebo in American College of Rheumatology (ACR) 50 response at Week 16. IZAR-1 is expected to enroll biologic-naïve patients and include an evaluation of radiographic progression, while IZAR-2 is expected to enroll patients with an inadequate response to tumor necrosis factor-α inhibitors (TNF-IR) — reflecting patients commonly seen in clinical practice — and is the first PsA trial to include a risankizumab active reference arm. Both trials will also assess a range of secondary endpoints reflecting the multiple disease manifestations characteristic of PsA. These include skin and nail outcomes, multidomain outcomes, and patient-reported outcome measures such as pain and quality of life assessments. Further details are available under NCT06641076 and NCT06641089 at ClinicalTrials.gov.

About Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic, progressive and complex inflammatory disease that manifests across multiple domains, leading to substantial functional impairment and decreased quality of life. The clinical features of PsA are diverse, comprising both musculoskeletal (peripheral arthritis, spondylitis, dactylitis, and enthesitis) and non-musculoskeletal (skin and nail disease) domains. PsA occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. Although the exact mechanism of disease is not fully understood, evidence suggests that activation of the IL-17 pathway plays an important role in the disease pathophysiology.

About the S-OLARIS trial

S-OLARIS is an open-label Phase 2 proof-of-concept trial aiming to investigate sonelokimab 60mg administered subcutaneously in approximately 25 patients with active axial spondylarthritis (axSpA). The primary endpoint is the change from baseline (CfB) at week 12 in the uptake of 18F-NaF in the sacroiliac joints and spine using PET in combination with MRI imaging. Throughout the trial, several other endpoints will be assessed including established clinical disease activity outcomes (e.g., ASAS), scores related to physical function, spinal mobility, and enthesitis as well as patient reported outcomes. The trial also includes an exploratory peripheral blood and tissue biomarker program.

About Axial Spondyloarthritis

Axial Spondyloarthritis (axSpA) typically impacts young people, with diagnosis based on chronic inflammatory back pain lasting more than three months with onset under 45 years of age. Advanced disease can lead to progressive and pathologic bone formation and joint fusion, severely limiting spinal mobility. Global reported prevalence of axSpA ranges from 0.5% to 1.5%. AxSpA can be categorized by disease progression into two subtypes: non-radiographic axSpA and ankylosing spondylitis (AS), also known as radiographic axSpA, which is diagnosed based on radiographic evidence of structural changes to the sacroiliac joints. Patients with axSpA experience fatigue, persistent morning stiffness, and pain that worsens at night and can disrupt sleep. Many patients also face the burden of comorbidities such as psoriatic arthritis and psoriasis. Studies have found elevated IL-17 levels in the blood and synovial fluid of patients with axSpA, and IL-17A and IL-17F are both thought to be key contributors to pathogenesis across the spondyloarthropathies.

About the LEDA Trial

The LEDA trial is a Phase 2 trial designed to evaluate the efficacy and safety of sonelokimab 120mg administered subcutaneously in adult patients with palmoplantar pustulosis (PPP). The primary endpoint of the trial is percent change from baseline in Palmoplantar Psoriasis Area and Severity Index (ppPASI) with important secondary endpoints including ppPASI75 (at least 75% improvement in the ppPASI). The LEDA trial features an innovative translational research program using peripheral blood and tissue biomarkers as trial controls.

The trial design has been informed by previous successful studies of sonelokimab, including the landmark Phase 2 MIRA trial in hidradenitis suppurativa, which identified the optimal dosing and demonstrated the potential of sonelokimab to target deep tissue inflammation effectively.

About Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP) is characterized by the development of blister-like pustules within erythematous, scaly plaques on the palms and the soles of the feet. PPP typically develops in adulthood, more frequently impacts females. Patients frequently experience significant pain, burning, and itching sensations on the palms and soles of the feet which can be debilitating and impair their ability to work, sleep, or perform other activities of daily living. Currently, the treatment of PPP is challenging with a significant unmet need for novel therapies to reduce the symptom burden for patients. Evidence suggests that activation of the IL-17 pathway has an important role in disease pathophysiology.

Cautionary Statement Regarding Forward Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: trial design, plans for and timing of clinical trials; whether the regulatory agencies agree that the two statistical strategies, when reviewed together, provide substantial evidence of efficacy in the VELA program, recognizing that under the composite strategy, VELA-2 failed to show a statistically significant improvement over placebo at week 16 on the primary endpoint; enrollment for clinical trials, including the VELA-TEEN trial and the IZAR program; the efficacy and safety of sonelokimab for the treatment of adult HS, adolescent HS, PPP, PsA and axSpA, including in comparison to existing standards or care or other competing therapies, clinical trials and research and development programs; the anticipated timing of the results from those studies and trials, and potential market opportunities for sonelokimab and MoonLake’s anticipated cash position. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that interim data in the VELA trials are not consistent with the final 52-week data, risks and uncertainties associated with MoonLake’s business in general and limited operating history, difficulty enrolling patients in clinical trials, state and federal healthcare reform measures that could result in reduced demand for MoonLake’s product candidates and reliance on third parties to conduct and support its preclinical studies and clinical trials and the other risks described in or incorporated by reference into MoonLake’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.

Contacts:

MoonLake Immunotherapeutics Media & Investors Relations

Carla Bretes, Director IR & External Communications

[email protected]

ICR Healthcare

Mary-Jane Elliott, Namrata Taak, Ashley Tapp

Tel: +44 (0) 20 3709 5700

[email protected]

If you are looking for a source of income that outlives you, look into dividend ETFs that are time-tested over decades.

, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fortinet, Inc. (NASDAQ: FTNT) common stock between November 8, 2024 and August 6, 2025, both dates inclusive (the "Class Period"), have until November 21, 2025 to seek appointment as lead plaintiff of the Fortinet class action lawsuit.  Captioned Oklahoma Firefighters Pension and Retirement System v. Fortinet, Inc., No. 25-cv-08037 (N.D. Cal.), the Fortinet class action lawsuit charges Fortinet as well as certain of Fortinet's top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Fortinet class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-fortinet-inc-class-action-lawsuit-ftnt.html  

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Fortinet provides cybersecurity and convergence of networking and security solutions.

The Fortinet class action lawsuit alleges that: (i) defendants knew that the refresh cycle would never be as lucrative as they represented, nor could it, because it consisted of old products that were a "small percentage" of Fortinet's business; (ii) defendants misrepresented and concealed that they did not have a clear picture of the true number of FortiGate firewalls that could be upgraded; and (iii) while telling investors that the refresh would gain momentum over the course of two years, Fortinet misrepresented and concealed that it had aggressively pushed through roughly half of the refresh in a period of months, by the end of the second quarter of 2025.

The Fortinet class action lawsuit further alleges that on August 6, 2025, Fortinet revealed during its earnings call that Fortinet was already "approximately 40% to 50% of the way through the 2026 upgrade cycle at the end of the second quarter [of 2025]."  The complaint also alleges that defendants: (i) admitted that "it's hard[] for us to predict" the total number of FortiGates requiring an upgrade; (ii) suggested customers had "excess [firewall] capacity from [purchasing firewalls in] prior years" and therefore did not need to upgrade; and (iii) revealed that the refresh could not have had "much business impact" as it consisted of only a "small percentage" of Fortinet's business because the products were "12 to 15 years" old and had been sold at a time when Fortinet's business was 5-10 times smaller, meaning that the total number of FortiGates eligible for an upgrade was inherently limited.  On this news, the price of Fortinet common stock fell more than 22%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Fortinet common stock during the Class Period to seek appointment as lead plaintiff in the Fortinet class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Fortinet class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Fortinet class action lawsuit.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Fortinet class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation.  Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors.  In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 

Services may be performed by attorneys in any of our offices. 

Contact:

            Robbins Geller Rudman & Dowd LLP

            J.C. Sanchez, Jennifer N. Caringal

            655 W. Broadway, Suite 1900, San Diego, CA 92101

            800-449-4900

            [email protected] 

SOURCE Robbins Geller Rudman & Dowd LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of V.F. Corporation (NYSE: VFC) between October 30, 2023 and May 20, 2025, both dates inclusive (the “Class Period”), of the important November 12, 2025 lead plaintiff deadline.

SO WHAT: If you purchased V.F. Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of V.F. Corporation’s turnaround plans. Specifically, defendants provided investors with material information concerning V.F. Corporation’s turnaround plan (“Reinvent”), which in part focused on efforts to return the Vans brand to positive growth. The lawsuit alleges that defendants concealed that additional significant reset actions would be necessary to return the Vans brand to growth, and would result in significant setbacks to Vans’ revenue growth trajectory. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

SAN DIEGO, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare’s October 2024 initial public offering (the “IPO”), have until Monday, October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit. Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424, and pending in the District of Oregon, the KinderCare class action lawsuit charges KinderCare as well as certain of KinderCare’s executives and directors, KinderCare’s controlling shareholder, and the underwriters of the IPO with violations of the Securities Act of 1933.

If you suffered substantial losses and wish to serve as lead plaintiff of the KinderCare class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-kindercare-learning-companies-inc-class-action-lawsuit-klc.html

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: KinderCare provides early education and child care services in the United States. In the IPO, KinderCare sold over 27 million shares of common stock to investors at $24 per share, raising $648 million in gross offering proceeds.

The KinderCare class action lawsuit alleges that the registration statement for the IPO was false and/or misleading and/or failed to disclose that: (i) numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (ii) KinderCare did not provide the “highest quality care possible” at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; and (iii) as a result, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss.

Since the IPO, the price of KinderCare stock fell to lows near $9 per share.

The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased KinderCare common stock in or traceable to the IPO to seek appointment as lead plaintiff in the KinderCare class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the KinderCare class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the KinderCare class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the KinderCare class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez, Jennifer N. Caringal
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Lineage, Inc. (NASDAQ: LINE) common stock pursuant and/or traceable to the registration statement issued in connection with Lineage’s July 2024 initial public offering (the “IPO”) of the important September 30, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Lineage common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lineage class action, go to https://rosenlegal.com/submit-form/?case_id=43296 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the registration statement was false and/or misleading and/or failed to disclose that: (1) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage’s customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage’s customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (2) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (3) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (4) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (5) consequently, Lineage’s financial results, business operations, and prospects were materially impaired. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lineage class action, go to https://rosenlegal.com/submit-form/?case_id=43296 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track.

Pfizer (PFE 0.64%) has a huge 7.1% dividend yield. That certainly compares favorably to the broader market's 1.2% yield and the average healthcare stock's yield of 1.7%. But Pfizer's lofty yield only exists because of a worrying 55% stock price decline since late 2022.

That kind of price decline doesn't happen by accident, which means you need to carefully consider whether this high-yield stock is worth adding to your income portfolio. Let's dig in and try to find out.

Image source: Getty Images.

What does Pfizer do?
Pfizer is one of the largest pharmaceutical companies in the world. It has a very long and successful history of finding, developing, and selling drugs, including dealing with the very difficult task of getting promising drugs approved for human use. It competes well with other drug makers and it is highly unlikely that the business is going to go away anytime soon.

That said, the stock has fallen a shocking 55% since late 2022. Even well-run businesses go through hard times and, pretty clearly, this is a hard time for Pfizer. There are two broad issues to consider.

First, there's been a shift in the view of drug makers, driven by reduced trust among consumers since the COVID-19 pandemic. That has been particularly troubling for Pfizer, which happens to make vaccines, which are an increasingly contentious issue in the public sphere.

The mood shift has come against another important trend for Pfizer, but one that is fairly normal in the pharma space. Drug companies are granted temporary exclusivity on new drugs because of the cost of drug development. When those drugs lose their patent protections generic alternatives can be produced, usually leading to a material drop in revenue for the original drug.

This is called a patent cliff in the industry and Pfizer is nearing just such a cliff starting in 2027, when oncology drug Ibrance comes off patent. That will be followed in 2028 with cardiovascular drugs Eliquis and Vyndaqel losing patent protections in 2028.

PFE data by YCharts

Pfizer is doing what needs to be done
Pfizer can't do much about the negative view of vaccines other than wait for the mood to shift. It likely will, given the long history of vaccines improving health outcomes. But the company can do something about patent cliffs, which basically require the healthcare giant to invest in new drugs.

One way it does this is with internal research and development. The problem is that R&D is an inherently lumpy process, so success isn't guaranteed and isn't likely to unfold on a set time frame that coincides with the company's patent expirations. A recent high profile failure came in the obesity drug arena.

But there's another option. Pfizer is large enough to simply go out and buy other companies with promising drugs. It did just that recently when it agreed to buy Metsera (MTSR -0.49%). The agreement calls for an upfront payment of $47.50 per share for Metsera, or about $4.9 billion in total. However, there are three contingent payments that could add up to $22.50 per share to the deal, increasing the overall cost by billions of dollars.

The key goal of the transaction is to get access to Metsera's promising drug pipelines, including in the obesity space. This is good news for Pfizer's business and management is, basically, doing what it needs to do to ensure the company's long-term success.

Before you run out and buy high yield Pfizer, however, consider two more facts. Pfizer's trailing 12-month dividend payout ratio is a lofty 90%, which suggests that the dividend may not be as secure as some investors might like. And the board of directors chose to cut the dividend in 2009 following Pfizer's acquisition of Wyeth Pharmaceuticals.

The $68 billion Wyeth deal was a larger transaction, but with such a high dividend payout ratio, the risk of a dividend cut following a material acquisition shouldn't be ignored. Also important to consider here is the fact that the drug candidates Pfizer is acquiring aren't guaranteed to be blockbuster drugs, which is why an earnout model was used in determining the price of the deal.

Buy the business, not the dividend
Given the steep price decline, there is turnaround appeal in Pfizer's stock today. And notably, management and the board are doing what is necessary to get the company back on track, namely investing (internally and via acquisition) in new drugs. It is highly likely that Pfizer does, eventually, get back on the growth track.

But the lofty payout ratio and a history of cutting the dividend suggests that income seekers should probably tread with caution. This pharma giant may not be as safe a dividend stock as you want it to be.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

If you are looking for reliable businesses to add to your portfolio while the market flirts with all-time highs, these dividend payers need to be on your short list.

The S&P 500 (SNPINDEX: ^GSPC) index is hovering around its all-time highs, and stretched valuations are making buying stocks a bit more worrisome right now. Don't fret: Whether you have $1,000 or $100,000 that you're ready to invest, you have options. Three strong possibilities to buy right now are integrated energy giant Chevron (CVX -0.37%), utility giant NextEra Energy (NEE 1.59%), and beverage giant Coca-Cola (KO -0.52%). Here's a look at each of these reliable dividend stocks.

1. Chevron is built to survive hard times
Chevron's business is diversified across the energy landscape, with assets in the energy production, energy transportation, and chemicals and refining segments. Each of these parts of the energy sector performs a bit differently through the phases of the energy cycle, so having exposure to all of them helps cushion Chevron against the impacts of soaring or slumping commodity prices.

On top of that, Chevron happens to have one of the strongest balance sheets among its close peers, with a debt-to-equity ratio of 0.2. During energy sector downturns, when its earnings slide, Chevron has the flexibility to take on debt to support its business and dividend. When energy prices recover, as they always have historically, it can (and does) pay those debt levels down again.

Its combination of a diversified business model and a strong financial foundation has allowed Chevron to increase its dividend annually for 38 consecutive years. That's an incredible streak given the inherent volatility of the energy sector. At the current share price, its dividend yield is about 4% -- well above average for the broader market and the energy industry specifically. So if you're in search of a reliable high-yield stock, you might want to put Chevron on your short list. A $1,000 investment would buy you about six shares of the stock.

Image source: Getty Images.

2. NextEra Energy is a dividend growth machine
NextEra Energy is really two businesses in one. First, the company operates regulated utilities, largely in Florida. The Sunshine State has long benefited from in-migration, and a growing base of customers means more revenues for NextEra and an easier time getting rate hikes and capital investment approved by government regulators. On top of that, NextEra has built one of the world's largest solar and wind power businesses. This is its major growth driver -- the company expects to roughly double its clean energy capacity over the next few years.

The key factor that attracts investors to NextEra stock, however, is its dividend. At the current share price, its dividend yield is around 3.1%, which is above the 2.7% average for a utility. And, on top of that, NextEra has grown its payouts at an annualized clip of 10% a year over the last decade. That would be a really good clip for just about any company, but for a utility, it's even more impressive. And based on management's forecasts, it will keep that pace up through at least 2026.

If you like dividend growth stocks, this relatively boring utility could be right up your alley. An investment of $1,000 would buy you roughly 13 shares.

3. Coca-Cola is fairly priced
Coca-Cola is the least attractive of this trio from a dividend yield perspective, given that it "only" pays 3% or so at its current share price. That yield, however, is well above the 1.2% average of the S&P 500 index and tops the consumer staples sector's average of about 2.5%. The big draw here is that Coca-Cola is a Dividend King -- one of the rare companies with dividend-hiking streaks of 50 straight years or more. Coca-Cola's streak, in fact, has run for 64 years.

It's also one of the best-known companies on the planet, selling an array of beverages from its namesake cola and other soft drinks to juices, energy drinks, coffee, and tea. Right now, consumers generally seem to be growing more interested in eating healthy, which has Wall Street a bit worried about the soda maker's future. That helps explain why a stock sell-off has pushed its price-to-sales and price-to-earnings ratios below their five-year averages.

Coca-Cola, though, has navigated through hard times before and will likely be able to do so again. So with the stock trading at a reasonable valuation, there's an opportunity here for new investors. 

If you like to own the most reliable dividend stocks, Coca-Cola should be on your watch list, if not your buy list, right now. A $1,000 investment will buy you around 15 shares.

Plenty of options even in an expensive market
It would be understandable for investors to think that with the S&P 500 at such a lofty level, there are no good deals on stocks to be found right now. Yet Chevron, NextEra Energy, and Coca-Cola show that's not the case. 

They are three of the best dividend choices out there today, but there are other similarly appealing options available if you look for them. Just make sure you take both the risks and the potential rewards into consideration whenever you examine a business. Each member of this trio has proven it has what it takes to survive the economy's rough patches and keep paying shareholders well all along the way.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron and NextEra Energy. The Motley Fool has a disclosure policy.

September 28, 2025 11:15 ET

 | Source:

BridgeBio Pharma, Inc.

- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo

- Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001)

- The difference in cumulative events increased progressively with results at Month 30 showing 53 events were avoided per 100 treated participants (95% CI:29–79)

PALO ALTO, Calif., Sept. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, presented data from the ATTRibute-CM study showing that acoramidis reduced cumulative cardiovascular outcomes, including cardiovascular mortality (CVM) or recurrent cardiovascular-related hospitalizations (CVH), within the first month of treatment in patients with ATTR-CM. These data were presented in a Late Breaking Clinical Trials Oral Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2025 and simultaneously published in Journal of the American College of Cardiology. Acoramidis is a selective, small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

“Acoramidis demonstrated early and sustained clinical efficacy on the totality of cumulative cardiovascular outcomes, where accrued events start to numerically diverge within the first month of treatment,” said Ahmad Masri, M.D., M.S. of Oregon Health & Science University. “As a practicing cardiologist, these findings are incredibly meaningful because it draws attention to the time-sensitive nature of transthyretin amyloidosis diagnosis and treatment initiation, where a safe and effective treatment such as acoramidis can potentially have an early effect on reducing patients' risk of cardiovascular hospitalizations and events.”

Details from the late breaking oral presentation, Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM, presented by Dr. Masri included:

At Month 1, numerically fewer cumulative events were observed with acoramidis compared to placeboAcoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001)The difference in cumulative events increased progressively with results at Month 30 showing 53 events were avoided per 100 treated participants (95% CI:29–79)In addition to the late breaking oral presentation, a simultaneous publication in Journal of the American College of Cardiology, with the same title as the presentation, noted the same details and also concluded that at Month 42, CVM was reduced with continuous acoramidis versus placebo-to-acoramidis with a hazard reduction of 45% (p=0.0011) In addition to the late breaking oral presentation and simultaneous publication of the cumulative cardiovascular outcomes data from ATTRibute-CM, one oral presentation and three poster sessions were shared on the open-label extension data from ATTRibute-CM and real-world evidence. These findings included:

Continuous Acoramidis Treatment Significantly Reduced Risk of All-cause Mortality and Cardiovascular-related Hospitalization at Month 42, in Patients with Wild-type And Variant Transthyretin Amyloidosis Cardiomyopathy, shared in an oral presentation by Lily Stern, M.D. of Cedars-Sinai Heart Institute At Month 42, continuous acoramidis was associated with lower risk of all-cause mortality (ACM), first CVH, and ACM/first CVH vs placebo to acoramidis switch in both wild-type ATTR-CM and variant ATTR-CM, highlighting the importance of early and continuous acoramidis regardless of TTR genotype Acoramidis Mitigates the Rise in NT-proBNP Levels Observed with Placebo in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM, presented in a poster session by Nitasha Sarswat, M.D. of UChicago Medicine In the variant ATTR-CM subpopulation from ATTRibute-CM, acoramidis consistently mitigated the rise in N-terminal pro-B-type natriuretic peptide (NT-proBNP) observed in the placebo variant group, with effects starting at Month 3, and continuing through Month 30. Considering the higher risk posed by variant ATTR-CM, these findings are especially relevant in addressing the distinct medical needs of the variant ATTR-CM patient population Effect of Acoramidis on Cardiac Conduction Abnormalities in Transthyretin Amyloid Cardiomyopathy, presented in a poster session by Brett W. Sperry, M.D. of Saint Luke's Health System In ATTRibute-CM, acoramidis treatment was associated with numerically lower percentages of participants with worsening, prolonged PR or QRS intervals at Month 24 and Month 30, compared with placebo. These observations are consistent with the slowing of ATTR-CM disease progression previously reported with acoramidis State-Level Differences in Incidence of Transthyretin Amyloid Cardiomyopathy in United States Veterans Persist After Introduction of Disease-Modifying Therapy, presented in a poster session by Sandesh Dev, M.D. of Arizona State University The incidence of ATTR-CM in the U.S. Veteran population increased nationally in the setting of available treatment, possibly due to improved awareness in most states Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency with all labels specifying near-complete stabilization of TTR.

More data on the benefit of Attruby for ATTR-CM patients is planned for future medical meetings.

About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio Pharma (BridgeBio; NASDAQ:BBIO) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.  For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “potential,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements regarding the potential of acoramidis to have an early effect on reducing patients’ risk of cardiovascular hospitalizations and events, the timing of future data disclosures, and BridgeBio’s ongoing development pipeline, reflect BridgeBio’s current views about its plans, intentions, expectations, and strategies, which are based on the information currently available to BridgeBio and on assumptions it has made. Although BridgeBio believes that its plans, intentions, expectations, and strategies as reflected in or suggested by these forward-looking statements are reasonable, it can give no assurance that such plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties, and assumptions, including, but not limited to: the risks associated with BridgeBio’s dependence on third parties for development; regulatory authorities requiring additional studies or data to support the continued or expanded commercialization of acoramidis; whether data and results meet regulatory requirements or are sufficient for continued development, review, or approval; and whether other regulatory agencies agree with BridgeBio’s strategies or data interpretations. These risks also include impacts from global health emergencies, such as delays in regulatory reviews and other activities, manufacturing and supply chain interruptions, adverse effects on healthcare systems, and disruption of the global economy; and the impacts of macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, increasing inflation rates, and fluctuating interest rates on BridgeBio’s operations and expectations. Additional risks are described in the Risk Factors section of BridgeBio’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission. Moreover, BridgeBio operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of BridgeBio’s management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these statements. Except as required by applicable law, BridgeBio assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
[email protected]  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]

Forget consumer chatbots -- IBM is targeting a much more lucrative AI market. Here's the overlooked opportunity that could drive massive growth for Big Blue's AI business.

With other tech giants sparring over consumer chatbots, IBM (IBM 1.22%) is quietly positioning itself to dominate a different artificial intelligence (AI) battlefield: the enterprise segment.

The centennial tech titan might seem like an unlikely AI winner, but there's one key factor that could make IBM the surprise star of the artificial intelligence revolution. IBM's AI solutions are tailor-made for large corporations.

Image source: Getty Images.

IBM's secret weapon: Enterprise-class AI
The watsonx platform for generative AI services isn't trying to write your poetry or plan your vacation. Instead, it's helping Fortune 500 companies deploy AI with strict attention to data security and regulatory requirements. Combined with Red Hat's OpenShift platform -- IBM's $34 billion acquisition from 2019 that's now paying proverbial dividends -- the company offers something unique: AI that works within existing enterprise infrastructure.

This isn't just theory. Banks are using IBM's watsonx to detect fraud while maintaining compliance with financial regulations. Healthcare systems are deploying IBM's AI to analyze patient data without violating patient privacy regulations.

It's all done with auditable data flows. Sure, watsonx will hallucinate from time to time, like any other system based on large language models (LLMs). But when it does, you'll be able to trace the error back to its original inspiration.

Meanwhile, IBM's consulting arm helps these enterprises make use of AI solutions. This unique focus on support services creates sticky, long-term business relationships.

The big blue numbers tell the story
IBM's AI-based Automation segment grew 14% year over year in Q2 2025, while Red Hat revenue continues its double-digit revenue expansion. The enterprise AI market is projected to reach $600 billion by 2028, and IBM is uniquely positioned to capture this opportunity.

Unlike consumer AI companies burning cash on compute costs, IBM's enterprise focus means higher margins and predictable revenue streams. While others chase the next viral chatbot, IBM is selling the picks and shovels of the enterprise AI gold rush -- and that's exactly why it will thrive. Buying IBM stock today should set you up for robust AI-boom gains.

Anders Bylund has positions in International Business Machines. The Motley Fool has positions in and recommends International Business Machines. The Motley Fool has a disclosure policy.

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Snap Inc. (NYSE: SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), both dates inclusive, of the important October 20, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Snap securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Snap class action, go to https://rosenlegal.com/submit-form/?case_id=2663 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Snap’s expected advertising revenue and anticipated growth while emphasizing potential macroeconomic instability. In truth, Snap’s optimistic reports of advertising growth and earnings potential fell short of reality as they relied far too heavily on Snap’s ability to execute on its potential; Snap was already experiencing the ramifications of a significant execution error when defendants’ claimed a lack of visibility due to macroeconomic conditions. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Snap class action, go to https://rosenlegal.com/submit-form/?case_id=2663 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PubMatic, Inc. (NASDAQ: PUBM) between February 27, 2025 and August 11, 2025, both dates inclusive (the “Class Period”), of the important October 20, 2025 lead plaintiff deadline.

SO WHAT: If you purchased PubMatic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the PubMatic class action, go to https://rosenlegal.com/submit-form/?case_id=43810 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) a top demand side platform (“DSP”) buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) as a result, PubMatic was seeing a reduction in ad spend and revenue from this top DSP buyer; and (3) as a result of the foregoing, defendants’ positive statements about PubMatic’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the PubMatic class action, go to https://rosenlegal.com/submit-form/?case_id=43810 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com